Nvelop Therapeutics

At Nvelop, we are working to address the complex challenge of effectively delivering genetic medicines to target cells within the body (in vivo) in order to help treat patients with previously undruggable diseases. Our team is advancing two next-generation delivery platforms, started in the labs of our scientific co-founders Dr. David Liu of the Broad Institute of MIT and Harvard, and Dr. Keith Joung formerly of Mass General Hospital. We will use these platforms to build a pipeline of therapeutics internally and to enable strategic partners. We are building a culture and organization to support this important mission, bringing together individuals that thrive in a supportive environment where diverse perspectives and a passion for discovery drive cutting-edge science and breakthrough medicines. Read something that resonates? Reach out to careers@NvelopTx.com.